Amphastar Pharmaceuticals (AMPH) Cash from Financing Activities (2013 - 2026)

Amphastar Pharmaceuticals has reported Cash from Financing Activities for 14 years, with the latest figure at -$43.5 million in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 44.15% year-over-year to -$43.5 million in Q2 2026; TTM through Jun 2026 was -$96.5 million, a 4.84% increase from a year earlier, with the FY2025 full-year figure at -$67.4 million, up 16.71% from the prior year.
• Cash from Financing Activities was -$43.5 million for Q2 2026 at Amphastar Pharmaceuticals, down from -$30.2 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $428.1 million in Q2 2023, with the low at -$47.1 million in Q4 2023.
• Average Cash from Financing Activities over 5 years is $11.4 million, with a median of -$14.2 million recorded in 2022.
• The largest YoY upside for Cash from Financing Activities was 43169.52% in 2023 against a maximum downside of 391.48% in 2023.
• Over 5 years, Cash from Financing Activities stood at -$16.2 million in 2022, then plunged by 191.32% to -$47.1 million in 2023, then gained by 28.12% to -$33.8 million in 2024, then surged by 45.71% to -$18.4 million in 2025, then sank by 136.95% to -$43.5 million in 2026.
• The last three Cash from Financing Activities figures came in at -$43.5 million (Q2 2026), -$30.2 million (Q1 2026), and -$18.4 million (Q4 2025), per Business Quant data.